{
  "drug_name": "Imipenem-cilastatin-relebactam",
  "tradename": "Recarbrio",
  "usage_and_dosing": {
    "general": [
      "Combination of imipenem-cilastatin, a carbapenem, with a beta-lactamase inhibitor, relebactam.",
      "Relebactam is a diazabicyclooctane beta-lactamase inhibitor that inhibits Ambler class A enzymes (including ESBLs, KPC) and class C enzymes (AmpC). However, it is not active vs Ambler class B metallo-beta-lactamases (VIM, IMP, NDM carbapenemases) or class D (OXA) carbapenemases.",
      "FDA approved for 3 indications:",
      "Hospital-acquired and ventilator-associated bacterial pneumonia in adults with limited or no alternative treatment options and caused by susceptible gram-negative bacteria: Actinetobacter calcoaceticus-baumannii, E. cloacae, E. coli, H. influenzae, Klebsiella spp., P. aeruginosa, S. marcescens.",
      "Complicated urinary tract infections in adults who have limited or no alternative treatment options, including pyelonephritis, and caused by susceptible gram-negative bacteria: E. cloacae, E. coli, Klebsiella spp., P. aeruginosa.",
      "Complicated intra-abdominal infections in adults who have limited or no alternative treatment options, and caused by susceptible gram-negative bacteria: Bacteroides spp., C. freundii, E. cloacae, E. coli, F. nucleatum, Klebsiella spp., Parabacteroides distasonis, P. aeruginosa.",
      "An alternative antibiotic for drug resistant genotypes.",
      "Imipenem-cilastatin-relebactam is predictably active in vitro vs. Enterobacterales, Bacteroides spp., and P. aeruginosa including isolates that produce ESBLs, AmpC, and serine-based carbapenemases, e.g., Klebsiella pneumoniae carbapenemase (KPC).",
      "It is predictably not active vs. MRSA, Enterococcus faecium, Stenotrophomonas maltophilia, and some Burkholderia species.",
      "Dosage is expressed as the sum of the three components.",
      "Review: Antimicrob Agents Chemother 2022;66:e0025622."
    ],
    "adult_dose": {
      "recommended_dose": "1.25 gm IV (over 30 min) q6h x4-14 days",
      "note": "1.25 gm = imipenem 500 mg + cilastatin 500 mg + relebactam 250 mg"
    },
    "pediatric_dose": {
      "note": "Doses are expressed as the sum of all three components",
      "amr_gram_negative_guidance": "J Pediatric Infect Dis Soc 2025;14:piaf004",
      "per_fda": {
        "safety_and_efficacy": "not established",
        "doses": {
            "age_lt_7_days": "125 mg/kg/day (div q12h)",
            "age_7_to_lt_28_days": "187.5 mg/kg/day (div q8h)",
            "age_ge_28_days": "250 mg/kg/day (div q6h)"
        },
        "cns_infection": "Not recommended for CNS infection",
        "max_day": "10 gm"
      }
    }
  },
  "renal_adjustment": {
    "half_life_normal": "Imipenem: 1",
    "half_life_esrd": "Imipenem: 4",
    "dose_renal_function_normal": "1.25 gm IV q6h",
    "crcl_or_egfr": "CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended",
    "hemodialysis": "0.5 gm q6h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment table."
  ],
  "adverse_effects": [
    "Hypersensitivity (e.g., fever, rash, anaphylaxis)",
    "Gastrointestinal (nausea, vomiting, diarrhea, C. difficile infection)",
    "Infusion site reactions",
    "Hematologic (anemia, eosinophilia, neutropenia)",
    "Headache, confusion",
    "Increased liver function tests",
    "Seizure risk, see Carbapenems, Overview. Increased risk if combined with valproic acid or divalproex sodium (avoid combination)."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Insufficient data in humans, evidence of embryofetal toxicity in animals",
    "lactation": "Safety not established, avoid use",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": ["Nocardia sp."],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "Imipenem: T>MIC, Relebactam: 24-hr AUC/MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "Imipenem: 104.3 µM, Relebactam: 64.0 µM (1.25 gm q6h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "Imipenem: 20, Cilastatin: 40, Relebactam: 22",
    "volume_of_distribution_vd_l": "Imipenem: 24.3 L, Cilastatin 13.8 L, Relebactam 19.0 L (all Vss)",
    "avg_serum_half_life_hr": "Imipenem: 1, Cilastatin: 1, Relebactam: 1.2",
    "elimination": "Renal",
    "bile_penetration_percent": "Imipenem: minimal",
    "csf_blood_percent": "Imipenem: 8.5, Relebactam: no data",
    "therapeutic_levels_in_csf": "No data 9",
    "auc_ug_hr_ml": "Imipenem: 573.9 µM-hr, Relebactam: 427.3 µM-hr (SS, 0-24 h)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": "Imipenem: OAT1, OAT3, Cilastatin: OAT1, OAT3, Relebactam: OAT3, OAT4, MATE1, MATE2-K",
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Ganciclovir",
          "effect": "↑ seizure risk",
          "management": "Avoid co-administration"
      },
      {
          "drug": "Valproic acid",
          "effect": "↓ valproic acid",
          "management": "Avoid co-administration"
      }
  ]
}
